Key Highlights
- 8.78% was the move in Obsidian Therapeutics, Inc. (NASDAQ:OBX), which traded at USD 13.13 on November 18, 2026, a calculated gain of USD 1.06 from a calculated prior close of USD 12.07 on 144.30 thousand shares.
- 9.42% was the move since the open after the stock opened 0.58% below the prior close, a calculated opening level near USD 12.00, so the advance came after 9:30 a.m. ET.
- 2028 is the year into which cash runway extends, with USD 324.4 million of cash and marketable securities at September 30, 2026 against a third quarter net loss of USD 50.7 million.
- 67% objective response rate, or 10 of 15 patients, was reported for amsoki-cel in advanced melanoma, with median progression-free survival of 8.3 months and no dose-limiting toxicities in the pooled safety set of 37.
What Moved Obsidian Therapeutics, Inc. (NASDAQ:OBX) in Trading on November 18, 2026 (+USD 1.06, +8.78%)
Shares traded at USD 13.13 in the regular session on November 18, 2026, up 8.78%. The calculated prior close for November 17, 2026 was USD 12.07 (price divided by 1.0878), so the calculated move was USD 1.06 per share. Volume was 144.30 thousand shares, a calculated traded value of about USD 1.89 million. The stock opened 0.58% below the prior close and then traded 9.42% above the open. Using 61.77 million shares outstanding from published market data, calculated market Capitalization is about USD 811.0 million at the traded price.
The Rationale: No Fresh Catalyst Beyond Amsoki-Cel Data for Obsidian Therapeutics, Inc. (NASDAQ:OBX)
No company announcement dated November 18, 2026 was identified in published coverage. As general context, the session followed the third quarter 2026 report of November 12, 2026 and updated Phase 1/2 data presented at the SITC 2026 annual meeting. Of 15 efficacy-evaluable patients, 10 responded, including 2 complete and 8 partial responses, and 5 of 15 (33%) were in deep, ongoing response at 12 months, with median follow-up of 14.3 months. Registration-enabling enrollment is expected to finish by the end of the first quarter of 2027, with topline data by year-end 2027. CEO Madan Jagasia said 2026 has been a transformative year so far.
Valuation, Liquidity and Risks for Obsidian Therapeutics, Inc. (NASDAQ:OBX)
Third quarter 2026 Research and Development expense was USD 27.5 million, general and administrative expense was USD 10.3 million, and acquired in-process research and development from the Galera transaction was USD 15.1 million, producing a net loss of USD 50.7 million, or USD 1.23 per share. Cash of USD 324.4 million is about 40.0% of the calculated market value. Risks include clinical and regulatory setbacks, a registration filing for the resale of up to 29.16 million shares by selling stockholders, which can create Supply overhang, and a pre-revenue profile.
Where Things Stand
Obsidian Therapeutics, Inc. (NASDAQ:OBX) traded at USD 13.13 on November 18, 2026, up 8.78% from a calculated prior close of USD 12.07, on volume of 144.30 thousand shares. The stock opened 0.58% lower and then rose 9.42% from the open. No catalyst dated that day was identified in published coverage. The latest report, filed November 12, 2026 for the quarter ended September 30, 2026, showed USD 324.4 million of cash, a net loss of USD 50.7 million and a runway into the second half of 2028. Milestones ahead include non-small cell lung cancer Phase 1 data in the first half of 2027 and melanoma topline data by year-end 2027, so the outcome of those readouts remains uncertain.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...